GU Cancers 2019 | DORA trial: radium-223 plus docetaxel for mCRPC

Michael Morris

Michael Morris, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the aims, rationale and implications of the DORA trial (NCT03574571), which investigated the effect of radium-223 with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video